We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon.
- Authors
Valkema, Maria J.; Spaander, Manon C. W.; Boonstra, Jurjen J.; van Dieren, Jolanda M.; Hazen, Wouter L.; Erkelens, G. Willemien; Holster, I. Lisanne; van der Linden, Andries; van der Linde, Klaas; Oostenbrug, Liekele E.; Quispel, Rutger; Schoon, Erik J.; Siersema, Peter D.; Doukas, Michail; Eyck, Ben M.; van der Wilk, Berend J.; van der Sluis, Pieter C.; Wijnhoven, Bas P. L.; Lagarde, Sjoerd M.; van Lanschot, J. Jan B.
- Abstract
Background: Active surveillance is being investigated as an alternative to standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer. It is unknown whether dysphagia persists or develops when the oesophagus is preserved after neoadjuvant chemoradiotherapy. The aim of this study was to assess the prevalence and severity of dysphagia during active surveillance in patients with an ongoing response. Methods: Patients who underwent active surveillance were identified from the Surgery As Needed for Oesophageal cancer ('SANO') trial. Patients without evidence of residual oesophageal cancer until at least 6 months after neoadjuvant chemoradiotherapy were included. Study endpoints were assessed at time points that patients were cancer-free and remained cancer-free for the next 4 months. Dysphagia scores were evaluated at 6, 9, 12, and 16 months after neoadjuvant chemoradiotherapy. Scores were based on the European Organisation for Research and Treatment of Cancer oesophago-gastric quality-of-life questionnaire 25 (EORTC QLQOG25) (range 0-100; no to severe dysphagia). The rate of patients with a (non-)traversable stenosis was determined based on all available endoscopy reports. Results: In total, 131 patients were included, of whom 93 (71.0 per cent) had adenocarcinoma, 93 (71.0 per cent) had a cT3-4a tumour, and 33 (25.2 per cent) had a tumour circumference of greater than 75 per cent at endoscopy; 60.8 to 71.0 per cent of patients completed questionnaires per time point after neoadjuvant chemoradiotherapy. At all time points after neoadjuvant chemoradiotherapy, median dysphagia scores were 0 (interquartile range 0-0). Two patients (1.5 per cent) underwent an intervention for a stenosis: one underwent successful endoscopic dilatation; and the other patient required temporary tube feeding. Notably, these patients did not participate in questionnaires. Conclusion: Dysphagia and clinically relevant stenosis are uncommon during active surveillance.
- Subjects
ESOPHAGEAL cancer; WATCHFUL waiting; DEGLUTITION disorders; TUBE feeding; CHEMORADIOTHERAPY; CANCER treatment
- Publication
British Journal of Surgery, 2023, Vol 110, Issue 10, p1381
- ISSN
0007-1323
- Publication type
Article
- DOI
10.1093/bjs/znad211